Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalised medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.
For more information on Debiopharm Group™, please visit: http://www.debiopharm.com.
About Debio R.P.
Debio Recherche Pharmaceutique (Debio R.P.), based in Martigny ( Switzerland), is a pharmaceutical research, development and production company that has been Swissmedic and ANVISA ( Brazil) certified, as well as inspected and registered by the American Food and Drug Administration (FDA) and the KFDA ( South Korea). Debio R.P. is active in the discovery, formulation and development of peptides. Debio R.P. forms part of Debiopharm Group™ and employs 130 people, half of whom are university graduates or engineers.About Dr. Reddy's Dr. Reddy's Laboratories Ltd. (NYSE: RDY) (Dr. Reddy's) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to: http://www.drreddys.com Debiopharm S.A. Contact Maurice Wagner Director Corporate Affairs & Communication Tel.: +41(0)21-321-01-11 Fax: +41(0)21-321-01-69 firstname.lastname@example.org Dr. Reddy' s Contact S. Rajan email@example.com Tel.: +91-40-49002445 Additional Media Contacts In London Maitland Brian Hudspith Tel.: +44(0)20-7379-5151 firstname.lastname@example.org In New York Russo Partners, LLC Martina Schwarzkopf, Ph.D. Account Executive Tel.: +1-212-845-4292 Fax: +1-212-845-4260 email@example.com Investors and Financial Analysts: Kedar Upadhye firstname.lastname@example.org Tel.: +91-40-66834297 Saunak Savla email@example.com Tel.: +91-40-49002135 Milan Kalawadia ( USA) firstname.lastname@example.org Tel.: +1-908-203-4931 SOURCE The Debiopharm Group